GT Medical CEO Matt Likens Sets a New BHAG – Giving Longer Lives to People with Brain Tumors

GT Medical CEO Matt Likens Sets a New BHAG – Giving Longer Lives to People with Brain Tumors

EPISODE 126

Matt Likens’ two decades-plus at Baxter cultivated in him a desire to deliver “critical therapies for life-threatening conditions.” He found great success as CEO of Ulthera, an aesthetics company using ultrasound energy, but once that company was sold to Merz he sought a way back to developing devices that can help sick people become well. He found such an opportunity at GT Medical Technologies, developer of collagen-based GammaTiles – tiles that deliver postsurgery radiation to prevent the regrowth of tumors in residual cells. In this podcast, Likens details the benefits of GT’s STaRT therapy. This is his second stint as a start-up CEO and Likens shares the successful approaches he’s borrowing from Ulthera including setting a Big Hairy Audacious Goal (BHAG) – “Creating the New Standard of Care for Patients with Brain Tumors.” He also mentions the company’s six operating principles:

  • Constructive Engagement
  • Collaboration
  • Consistency
  • Compliance
  • Ingenuity
  • Value

Enjoy.

Podcast Guest

Matt Likens

Matt Likens

President & CEO

GT Medical Technologies

Mr. Likens is the President and CEO of GT Medical Technologies. He comes to GT having previously led Ulthera from pre-commercial to over $100M in revenue and a $600M exit. His prior experience includes 5 years as President of GMP Wireless Medical and a 23 year career at Baxter,leading business units in both the US and Europe.

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the Medtech Talk Podcast, please complete the application today.

Meet Our Host

TOM SALEMI

Tom Salemi

A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.

Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!